EyeGate Pharmaceuticals, Inc. (EYEG)
USD 35.56
(-0.73%)
USD 35.56
(-0.73%)
| Breakdown | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.31 Million | -8.15 Million | -10.84 Million | -6.46 Million | -8.41 Million | -4.45 Million |
| Net Income | -8.09 Million | -7.09 Million | -10.81 Million | -13.21 Million | -13.34 Million | -8.39 Million |
| Depreciation & Amortization | 33.39 Thousand | 213.93 Thousand | 38.48 Thousand | 19.28 Thousand | 5185.00 | 1257.00 |
| Deferred income taxes | 12.05 Thousand | 95.39 Thousand | 86.04 Thousand | -1.34 Million | - | - |
| Stock-based compensation | 723.85 Thousand | 852.23 Thousand | 875.28 Thousand | 870.3 Thousand | 510.99 Thousand | 1.22 Million |
| Change in working capital | -2.87 Million | -1.7 Million | 10.98 Million | -3.22 Million | -9.18 Million | 10.83 Million |
| Other non-cash items | 2.87 Million | -514.25 Thousand | -12.02 Million | 10.42 Million | 13.59 Million | -8.12 Million |
| Investing Cash Flow | -244.43 Thousand | - | -270 Thousand | -36.99 Thousand | 149.74 Thousand | -20 Thousand |
| Investments in PPE | -133.79 Thousand | - | -270 Thousand | -36.99 Thousand | -11 Thousand | - |
| Acquisitions | -110.64 Thousand | - | - | - | 185.74 Thousand | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | -25 Thousand | -20 Thousand |
| Financing Cash Flow | 4.99 Million | 3.92 Million | 11.3 Million | 10.67 Million | 3.49 Million | 12.61 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 5 Million | 1.77 Million | 10.1 Million | 11.92 Million | 3.76 Million | 14.1 Million |
| Other Financing Activities | -2497.00 | 2.14 Million | 1.19 Million | -1.25 Million | -270.47 Thousand | -1.48 Million |
| Accounts receivables | -18.95 Thousand | - | - | - | - | -907.5 Thousand |
| Accounts payables | 136.69 Thousand | 146.63 Thousand | -642.43 Thousand | -706.03 Thousand | 712.79 Thousand | -148.25 Thousand |
| Inventory | -3.02 Million | - | - | - | - | 5.86 Million |
| Other working capital | 37.82 Thousand | -1.85 Million | 11.63 Million | -2.51 Million | -9.89 Million | 6.02 Million |
| Cash at beginning of period | 3.82 Million | 8.04 Million | 7.85 Million | 3.68 Million | 8.39 Million | 167 Thousand |
| Cash at end of period | 1.23 Million | 3.82 Million | 8.04 Million | 7.85 Million | 3.63 Million | 8.39 Million |
| Capital Expenditure | -133.79 Thousand | - | -270 Thousand | -36.99 Thousand | -11 Thousand | - |
| Effect of forex changes on cash | -26.93 Thousand | 5503.00 | 7915.00 | 4992.00 | 6298.00 | 90.04 Thousand |
| Net cash flow / Change in cash | -2.59 Million | -4.22 Million | 198.2 Thousand | 4.17 Million | -4.75 Million | 8.22 Million |
| Free Cash Flow | -7.45 Million | -8.15 Million | -11.11 Million | -6.5 Million | -8.42 Million | -4.45 Million |
| Breakdown | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 FY | 2020 Q4 | 2020 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -2.96 Million | -2.46 Million | -2.58 Million | -8.09 Million | -2.41 Million | -2 Million |
| Depreciation & Amortization | 11.05 Thousand | 12.6 Thousand | 10.59 Thousand | 33.39 Thousand | 9056.00 | 8638.00 |
| Deferred income taxes | - | - | - | 12.05 Thousand | 12.05 Thousand | - |
| Stock-based compensation | 149.46 Thousand | 262.89 Thousand | 216.94 Thousand | 723.85 Thousand | 193.15 Thousand | 187.73 Thousand |
| Change in working capital | 6.93 Million | -490.46 Thousand | 5.52 Million | -2.87 Million | -2.52 Million | -1.81 Million |
| Other non-cash items | -6.39 Million | 46.89 Thousand | -5.74 Million | 2.87 Million | 3.02 Million | 1.88 Million |
| Investing Cash Flow | - | -5746.00 | -58.11 Thousand | -244.43 Thousand | -244.43 Thousand | -498.68 Thousand |
| Investments in PPE | - | -5746.00 | -58.11 Thousand | -133.79 Thousand | -20.07 Thousand | - |
| Acquisitions | - | - | - | -110.64 Thousand | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | -224.36 Thousand | - |
| Financing Cash Flow | 9.75 Million | -278.19 Thousand | 8.03 Million | 4.99 Million | 218 Thousand | 498.68 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 7.98 Million | 5 Million | -5 Million | 498.68 Thousand |
| Other Financing Activities | 9.75 Million | -278.19 Thousand | 50 Thousand | -2497.00 | 5.21 Million | -498.68 Thousand |
| Accounts receivables | - | - | - | -18.95 Thousand | -21.26 Thousand | - |
| Accounts payables | 132.56 Thousand | -165.02 Thousand | 22.58 Thousand | 136.69 Thousand | 287.45 Thousand | -34.76 Thousand |
| Inventory | - | - | - | -3.02 Million | -2.83 Million | - |
| Other working capital | 6.79 Million | -325.44 Thousand | 5.5 Million | 37.82 Thousand | 37.82 Thousand | -1.77 Million |
| Cash at beginning of period | 3.7 Million | 6.65 Million | 1.23 Million | 3.82 Million | 2.97 Million | 4.73 Million |
| Cash at end of period | 11.15 Million | 3.7 Million | 6.65 Million | 1.23 Million | 1.23 Million | 2.97 Million |
| Capital Expenditure | - | -5746.00 | -58.11 Thousand | -133.79 Thousand | -20.07 Thousand | - |
| Effect of forex changes on cash | -42.53 Thousand | -25.95 Thousand | 14.12 Thousand | -26.93 Thousand | -9767.00 | -17.32 Thousand |
| Net cash flow / Change in cash | 7.44 Million | -2.94 Million | 5.42 Million | -2.59 Million | -1.74 Million | -1.75 Million |
| Free Cash Flow | -2.27 Million | -2.64 Million | -2.62 Million | -7.45 Million | -1.72 Million | -1.74 Million |
UOLGY
TS0U
NRC
9651
RES
RISE